Sensyne strikes one-year agreement with Exscientia

Sensyne Health said on Friday that under the terms of the agreement, Exscientia will make an upfront payment for four SENSIGHT subscriptions and a project-based fee, with a 40/60 split between the two.

The AIM-listed group stated it would apply its "data science expertise" to create "bespoke data sets" from its database of patient records in order to answer project-specific questions regarding biomarker discovery and targets for new medicines.

Sensyne added that its collaborative relationship with the National Health Service meant it was able to capture "a more complete record of a patient's treatment" over a longer period of time than typically possible.

Chief executive Paul Drayson said: "Exscientia is a leader in AI-driven drug discovery and has already brought several AI-designed drug candidates to the clinical trial stage. We are excited about the opportunity to explore how we can work together to apply AI throughout the drug development process to bring new medicines to patients faster and more cost effectively."

As of 0825 GMT, Sensyne shares were down 0.64% at 78.0p.